Zayas-Jaime FJ, Ornelas-Aguirre JM, Pérez-Nápoles DE

Language: Spanish
References: 36
Page: 593-601
PDF size: 176.90 Kb.

ABSTRACT

Background: Hormone replacement therapy (HRT) with tibolone used in the management of menopause has low rates of acceptance and compliance in the first year. Few studies analyze the reasons for abandoning the use of tibolone.
Objective: To analyze the reasons for abandoned tibolone hormone replacement therapy in postmenopausal women and the effects of the drug through the years in the treatment.
Material and methods: In a cross-sectional study, were included 261 menopausal women between 40 and 60 year old who attended their disease control at the Gynaecological Endocrinology serving in the National Medical Center Northwest in Obregon City, Sonora, Mexico during 2010-2011. The variables studied included: age, type of menopause, time of use of HRT with tibolone, abandonment reason, development of hypertension, dyslipidemia, hypothyroidism and diabetes mellitus.
Results: A total of 21 women discontinued treatment (8.60%, 95% CI -3 to 19), p=0.0001. The reasons for abandonment included, 42.9% gynecological reasons (23.8% breast disease, 14.3% and 4.8% cervical condition ovarian pathology, p=0.0001). Liver disease and vascular occurred in 28.6%, p=0.050.
Conclusion: The women studied have adequate adherence to treatment with tibolone ( › 90%). We don´t show an increased risk of cardiovascular or metabolic disease in women studied. Further studies are needed to explore the long-term clinical course, therapeutic response and complications in menopausal patients who use HRT with tibolone.

REFERENCES

1. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: a Systematic Review to Update the U.S. Preventive Services Task Force Recommendations. Ann Intern Med 2012;157:104-113.

2. Clarkson TB. Does tibolone exacerbate atherosclerosis? European Heart Journal 2006;27:635-637.

3. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidlines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-28.

4. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23.

5. Panay N, Hamoda H, Arya R, Savvas M. The British Menopause Society and Women´s Health Concern. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59-68.

6. Egarter C, Huber J, Leikermoser R, Haidbauer R, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climateric complaints. Maturitas 1996;23:55-62.

7. Gregoriou O, Vitoratos N, Papadias C, Konidaris S, et al. Effect of tibolone on postmenopausal women with myomas. Maturitas 1997;27:187-191.

8. Carranza-Lira S. Relación de la terapia hormonal, la tibolona y los SERMs con el crecimiento de miomas en la mujer posmenopáusica. Ginecol Obstet Mex 2008;76:610-614.

9. Kenemans P, Bundred NJ, Foidart JM, Kubista E, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-146.

10. Beral V, Bull D, Reeves G, Million women study collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543- 1551.

11. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, et al. Effects of conjugated equine estrogen on stroke in the women´s health initiative. Circulation 2006;113:2425-2434.

12. Cummings SR, Ettinger B, Delmas PD, Kenemans P, et al. The effects of Tibolone in Older Postmenopausal Women. N Engl J Med 2008;359:697-708.

13. Villanueva LA, Ortega R, Morimoto S, Villanueva S, Arranz C. Efectos de la Tibolona sobre el metabolismo de lípidos, glucosa y secresión de insulina en mujeres posmenopáusicas. Ginecol Obstet Mex 1999;67:473- 477.

14. Rio de la Loza-Cava MF, Mendoza-Torres LJ, Murillo- Uribe A, Ortiz-Luna GF, et al. Evaluación clínica de la Tibolona en el síndrome climatérico. Perinatol Reprod Hum 1997;11:49-57.

15. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199- 208.

16. Stampfer MJ, Colditz GA, Willett WC, Manson JE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurse´s health study. N Engl J Med 1991;325:756-762.

17. Langer RD, Landgren BM, Rymer J, Helmond FA, OPAL Investigators. Effects of Tibolone and Continuous Combined Conjugated Equine Estrogen/Medroxyprogesterone Acetate on Endometrium and Vaginal Bleeding: Results of the OPAl Study. Am J Obstet Gynecol 2006;195:1320-1327.

18. Carranza-Lira S, Santos-González J. Mexican physicians perception about hormonal therapy after the Women’s Health Initiative Study. Rev Med Inst Mex Seguro Soc 2010;48:61-66.

19. Crespo-Retes I. Tibolona: 8 años de experiencia clínica. Rev Farmacol Terap 1994, 4:1-2.

20. Shifren JL, Schiff I. Role of Hormone Therapy in the Management of Menopause. Obstet Gynecol 2010;115:839- 855.

21. Hernández-Valencia M, Córdova-Pérez N, Basurto L, Saucedo R, et al. Frecuencia de los síntomas del síndrome climatérico. Ginecol Obstet Mex 2010;78:232-237.

22. Santen RJ, Craig-Allred D, Ardoin SP, Archer DF. Executive summary: Postmenopausal hormone therapy: an Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95:S1-S66.

23. Appt SE, Törmälä R, Franke AA, Mikkola TS, et al. Soy- Tibolone Combination-Effect on Lipids in Postmenopausal Monkeys and Women. Maturitas 2008;60:216- 222.

24. Koh KK, Han SH, Shin MS, Ahn JY, et al. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005;26:1362-1368.

25. Rossouw JE, Prentice RL, Manson JE, Wu L, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.

26. Neves-E-Castro M. Association of ovarian and uterine cancers with postmenopausal hormonal treatments. Clin Obstet Gynecol 2008;51:607-617.

27. Power ML, Zinberg S, Schulkin J. A survey of obstetriciangynecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 2006; 13(3): 434- 441.

28. López-Olmos J. Tratamiento hormonal sustitutivo de la menopausia con tibolona. Clin Invest Gin Obst 2005; 32(3):106-15.

29. Veerus P, Fischer K, Hakama M, Hemminki E, The EPHT Trial. Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial. BMC Med Res Methodol 2012;12:44.

30. Welton AJ, Vickers MR, Kim J, Ford D, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190.

31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women´s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

32. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:633-636.

33. Bracho M, Gil S. Tibolona y cáncer de mama. Revista del Climaterio 2004; 7:210-214.

34. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.

35. Arena JO. Incorporación y cumplimiento de la terapia de reemplazo hormonal del climaterio femenino antes y después del estudio del WHI: Revisión de la evidencia. Rev Chil Obstet Ginecol 2005;70:186-195.

36. Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but no low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006;55:278-287.